Market Overview:
The global sustained release ocular drug delivery systems market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of eye diseases, rising geriatric population, and technological advancements in ocular drug delivery systems. Based on type, the global sustained release ocular drug delivery systems market is segmented into liposomes, microcapsules/nanocapsules, microspheres/nanospheres, and implants. Liposomes are expected to account for the largest share of the global sustained release ocular drug delivery systems market in 2018 owing to their high efficiency and ability to target specific tissues. Based on application, cataract is estimated to be the largest segment of the global sustained release ocular drug delivery systems market in 2018 followed by glaucoma and corneal transplantation.
Product Definition:
Sustained release ocular drug delivery systems are devices or methods that deliver a drug to the eye over an extended period of time. They may be used to treat conditions such as glaucoma, macular degeneration, and dry eye syndrome. Sustained release ocular drug delivery systems are important because they can help to reduce the number of doses a patient needs to take, which can improve compliance and ultimately lead to better treatment outcomes.
Liposome:
Liposome is a small particle made up of lipids (fats) and phospholipids. It is formed by the fusion of one or more non-water-soluble lipid bilayer with water soluble cholesterol. The drug or cargo to be transported may be incorporated into the liposome either before or after its addition to water, depending on the type of liposomes produced.
Microcapsules/Nanocapsules:
Microcapsules/Nanocapsules are small vesicular systems composed of polymer membrane and a core of drug. They have been developed to overcome the limitations associated with traditional ocular drug delivery systems such as rapid absorption, high systemic exposure, and toxicity. Microcapsule/Nanocapsule has been designed to target retinal pigment epithelium (RPE) cells which are responsible for causing degenerative retinal disease (DRD).
Application Insights:
The cataract segment held the largest market share in 2017 and is anticipated to expand at a CAGR of XX% over the forecast period. The increasing geriatric population base across the globe is expected to be one of the key driving factors for this growth. For instance, as per UNPD, there are nearly 47 million people aged 60 years or above in China, 36 million in India and 23 million each in Brazil and Germany by 2050 respectively thus contributing towards sustained release ocular drug delivery systems market growth over forecast period.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to factors such as local presence of major players, high disposable income, and increasing awareness about ocular diseases. Moreover, approval and launch of novel products by key companies is expected to drive the regional market over the forecast period. For instance, in May 2018 Eisai Co., Ltd., received FDA approval for SUBLIMER 1 Test Strip System for rapid testing of patients with dry eye syndrome (DES). The product will be available during Q3 2018 in U.S.
Asia Pacific is expected to witness lucrative growth over the forecast period owing to rising geriatric population base coupled with growing disposable income especially in developing countries such as China.
Growth Factors:
- Increasing prevalence of eye diseases and disorders: The global prevalence of eye diseases is increasing at a rapid pace. This is primarily attributed to the changing lifestyles and growing aging population. According to the World Health Organization (WHO), there are around 285 million people who are visually impaired worldwide, out of which 39 million are blind and 246 million have low vision. The number of people with visual impairment is expected to increase to 456 million by 2050. This will create a large pool of potential patients for ocular drug delivery systems market players.
- Rising demand for minimally invasive procedures: There has been a rising demand for minimally invasive procedures in recent years, owing to their numerous benefits over traditional surgical procedures such as shorter recovery time, reduced pain, and lower risk of complications etc. Ocular drug delivery systems offer an attractive alternative to traditional surgery due its ability to provide targeted drug delivery directly into the eyes tissues minimizing systemic exposure and associated side effects.. This is likely to fuel the growth prospects of sustained release ocular drug delivery systems market in coming years
Scope Of The Report
Report Attributes
Report Details
Report Title
Sustained Release Ocular Drug Delivery Systems Market Research Report
By Type
Liposome, Microcapsules/Nanocapsules, Microspheres/Nanosptheres, Implants
By Application
Cataract, Glaucoma, Corneal Transplantation, Others
By Companies
pSivida, Allergan, Icon Bioscience, Ocular Therapeutix, Neurotech Pharmaceuticals, Santen Pharmaceutical, Aciont Inc., Envisia Therapeutics, GrayBug, Innocore Pharmaceuticals, OHR Pharmaceuticals, PolyActiva, TheraKine
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
156
Number of Tables & Figures
110
Customization Available
Yes, the report can be customized as per your need.
Global Sustained Release Ocular Drug Delivery Systems Market Report Segments:
The global Sustained Release Ocular Drug Delivery Systems market is segmented on the basis of:
Types
Liposome, Microcapsules/Nanocapsules, Microspheres/Nanosptheres, Implants
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Cataract, Glaucoma, Corneal Transplantation, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- pSivida
- Allergan
- Icon Bioscience
- Ocular Therapeutix
- Neurotech Pharmaceuticals
- Santen Pharmaceutical
- Aciont Inc.
- Envisia Therapeutics
- GrayBug
- Innocore Pharmaceuticals
- OHR Pharmaceuticals
- PolyActiva
- TheraKine
Highlights of The Sustained Release Ocular Drug Delivery Systems Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Liposome
- Microcapsules/Nanocapsules
- Microspheres/Nanosptheres
- Implants
- By Application:
- Cataract
- Glaucoma
- Corneal Transplantation
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Sustained Release Ocular Drug Delivery Systems Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Sustained release ocular drug delivery systems are devices that slowly release a medication into the eye over an extended period of time. This allows for consistent and steady dosing, which can be important for medications that need to be taken multiple times per day.
Some of the key players operating in the sustained release ocular drug delivery systems market are pSivida, Allergan, Icon Bioscience, Ocular Therapeutix, Neurotech Pharmaceuticals, Santen Pharmaceutical, Aciont Inc., Envisia Therapeutics, GrayBug, Innocore Pharmaceuticals, OHR Pharmaceuticals, PolyActiva, TheraKine.
The sustained release ocular drug delivery systems market is expected to grow at a compound annual growth rate of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Sustained Release Ocular Drug Delivery Systems Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Sustained Release Ocular Drug Delivery Systems Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Sustained Release Ocular Drug Delivery Systems Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Sustained Release Ocular Drug Delivery Systems Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Sustained Release Ocular Drug Delivery Systems Market Size & Forecast, 2018-2028
4.5.1 Sustained Release Ocular Drug Delivery Systems Market Size and Y-o-Y Growth
4.5.2 Sustained Release Ocular Drug Delivery Systems Market Absolute $ Opportunity
Chapter 5 Global Sustained Release Ocular Drug Delivery Systems Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Sustained Release Ocular Drug Delivery Systems Market Size Forecast by Type
5.2.1 Liposome
5.2.2 Microcapsules/Nanocapsules
5.2.3 Microspheres/Nanosptheres
5.2.4 Implants
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Sustained Release Ocular Drug Delivery Systems Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Sustained Release Ocular Drug Delivery Systems Market Size Forecast by Applications
6.2.1 Cataract
6.2.2 Glaucoma
6.2.3 Corneal Transplantation
6.2.4 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Sustained Release Ocular Drug Delivery Systems Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Sustained Release Ocular Drug Delivery Systems Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Sustained Release Ocular Drug Delivery Systems Analysis and Forecast
9.1 Introduction
9.2 North America Sustained Release Ocular Drug Delivery Systems Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Sustained Release Ocular Drug Delivery Systems Market Size Forecast by Type
9.6.1 Liposome
9.6.2 Microcapsules/Nanocapsules
9.6.3 Microspheres/Nanosptheres
9.6.4 Implants
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Sustained Release Ocular Drug Delivery Systems Market Size Forecast by Applications
9.10.1 Cataract
9.10.2 Glaucoma
9.10.3 Corneal Transplantation
9.10.4 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Sustained Release Ocular Drug Delivery Systems Analysis and Forecast
10.1 Introduction
10.2 Europe Sustained Release Ocular Drug Delivery Systems Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Sustained Release Ocular Drug Delivery Systems Market Size Forecast by Type
10.6.1 Liposome
10.6.2 Microcapsules/Nanocapsules
10.6.3 Microspheres/Nanosptheres
10.6.4 Implants
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Sustained Release Ocular Drug Delivery Systems Market Size Forecast by Applications
10.10.1 Cataract
10.10.2 Glaucoma
10.10.3 Corneal Transplantation
10.10.4 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Sustained Release Ocular Drug Delivery Systems Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Sustained Release Ocular Drug Delivery Systems Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Sustained Release Ocular Drug Delivery Systems Market Size Forecast by Type
11.6.1 Liposome
11.6.2 Microcapsules/Nanocapsules
11.6.3 Microspheres/Nanosptheres
11.6.4 Implants
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Sustained Release Ocular Drug Delivery Systems Market Size Forecast by Applications
11.10.1 Cataract
11.10.2 Glaucoma
11.10.3 Corneal Transplantation
11.10.4 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Sustained Release Ocular Drug Delivery Systems Analysis and Forecast
12.1 Introduction
12.2 Latin America Sustained Release Ocular Drug Delivery Systems Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Sustained Release Ocular Drug Delivery Systems Market Size Forecast by Type
12.6.1 Liposome
12.6.2 Microcapsules/Nanocapsules
12.6.3 Microspheres/Nanosptheres
12.6.4 Implants
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Sustained Release Ocular Drug Delivery Systems Market Size Forecast by Applications
12.10.1 Cataract
12.10.2 Glaucoma
12.10.3 Corneal Transplantation
12.10.4 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Sustained Release Ocular Drug Delivery Systems Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Sustained Release Ocular Drug Delivery Systems Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Sustained Release Ocular Drug Delivery Systems Market Size Forecast by Type
13.6.1 Liposome
13.6.2 Microcapsules/Nanocapsules
13.6.3 Microspheres/Nanosptheres
13.6.4 Implants
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Sustained Release Ocular Drug Delivery Systems Market Size Forecast by Applications
13.10.1 Cataract
13.10.2 Glaucoma
13.10.3 Corneal Transplantation
13.10.4 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Sustained Release Ocular Drug Delivery Systems Market: Competitive Dashboard
14.2 Global Sustained Release Ocular Drug Delivery Systems Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 pSivida
14.3.2 Allergan
14.3.3 Icon Bioscience
14.3.4 Ocular Therapeutix
14.3.5 Neurotech Pharmaceuticals
14.3.6 Santen Pharmaceutical
14.3.7 Aciont Inc.
14.3.8 Envisia Therapeutics
14.3.9 GrayBug
14.3.10 Innocore Pharmaceuticals
14.3.11 OHR Pharmaceuticals
14.3.12 PolyActiva
14.3.13 TheraKine
